ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer – Yahoo Finance

by

  1. ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
  2. Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma Medical Xpress
  3. Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer The ASCO Post
  4. New Ovarian Cancer Drug Extends Survival in Resistant Disease Medpage Today
  5. ImmunoGen stock jumps on Elahere cancer data (NASDAQ:IMGN) Seeking Alpha
  6. View Full Coverage on Google News

Read original article here

Leave a Comment